GAMLUGO
Live / Applied — Second extension granted (statement of use) (as of 13 Jan 2026)
What this means for you
Not registered yet, but its 16 May 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98554041
- Mark type
- Stylized text
- Filed
- 16 May 2024
- Published for opposition
- 03 Dec 2024
- Attorney of record
- Maury M. Tepper, III
Goods and services
- Class 005 — Pharmaceuticals: Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Owner
- Novartis AG, Basel, CH
- Novartis AG, Basel, CH
Prosecution history
- 14 Jan 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Jan 2026 — SOU EXTENSION 2 GRANTED
- 13 Jan 2026 — SOU EXTENSION 2 FILED
- 13 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Jul 2025 — SOU EXTENSION 1 GRANTED
- 11 Jul 2025 — SOU EXTENSION 1 FILED
- 11 Jul 2025 — SOU TEAS EXTENSION RECEIVED
- 14 Jan 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 03 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 03 Dec 2024 — PUBLISHED FOR OPPOSITION
- 27 Nov 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 07 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 04 Nov 2024 — ASSIGNED TO EXAMINER
- 16 May 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED